KTRA - Kintara Therapeutics, Inc. Stock Price, Fair Value and News

$4.000.00 (0.00%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

KTRA Price Action

Last 7 days

-26.2%

Last 30 days

0.6%

Last 90 days

-15.3%

Trailing 12 Months

-29.6%

KTRA RSI Chart

KTRA Valuation

Market Cap

169.1B

Price/Earnings (Trailing)

-22.5K

Price/Sales (Trailing)

36.4M

Price/Free Cashflow

-18.3K

KTRA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KTRA Fundamentals

KTRA Revenue

Revenue (TTM)

5.7K

KTRA Earnings

Earnings (TTM)

-7.5M

Earnings Growth (Yr)

27.04%

Earnings Growth (Qtr)

7.01%

KTRA Profitability

Return on Equity

-443.6%

Return on Assets

-181.62%

Free Cashflow Yield

-0.01%

KTRA Investor Care

Shares Dilution (1Y)

3268156.12%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2014	0	0	0	0
2013	0	13.8K	8.9K	5.7K
2012	11.4K	11.6K	12.3K	13.1K
2011	0	10.7K	10.9K	11.1K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

CEO	Mr. Robert E. Hoffman B.B.A., C.P.A., CPA
WEBSITE	kintara.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	3

Kintara Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Kintara Therapeutics, Inc.? What does KTRA stand for in stocks?

KTRA is the stock ticker symbol of Kintara Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kintara Therapeutics, Inc. (KTRA)?

As of Thu Dec 19 2024, market cap of Kintara Therapeutics, Inc. is 169.14 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KTRA stock?

You can check KTRA's fair value in chart for subscribers.

Is Kintara Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether KTRA is over valued or under valued. Whether Kintara Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Kintara Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KTRA.

What is Kintara Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 19 2024, KTRA's PE ratio (Price to Earnings) is -22494.8 and Price to Sales (PS) ratio is 36.38 Million. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KTRA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Kintara Therapeutics, Inc.'s stock?

In the past 10 years, Kintara Therapeutics, Inc. has provided -0.606 (multiply by 100 for percentage) rate of return.